Millennium Management
RAPP

Millennium Management’s Rapport Therapeutics RAPP Stock Holding History

Millennium Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10M Buy
319,552
+117,727
+58% +$3.31M ﹤0.01% 2169
2025
Q4 		$6.12M Buy
201,825
+47,651
+31% +$1.32M ﹤0.01% 2784
2025
Q3 		$4.58M Buy
+154,174
New +$2.75M ﹤0.01% 3237
2024
Q3 		– Sell
-116,782
Closed -$2.72M – 6559
2024
Q2 		$2.72M Buy
+116,782
New +$2.7M ﹤0.01% 3263

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Millennium Management's RAPP Position: Q1 2026 in Review

Millennium Management increased its Rapport Therapeutics (RAPP) stake by 58% in Q1 2026, buying an estimated $3.31M and bringing the position to 319,552 shares worth $10M. The position accounts for ﹤0.01% of the portfolio, ranked #2169.

Millennium Management first reported a position in RAPP in Q2 2024 and has held it in 4 quarters since. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Millennium Management held 319,552 shares of Rapport Therapeutics worth $10M as of Q1 2026.
  • Millennium Management bought 117,727 Rapport Therapeutics shares in Q1 2026, an estimated $3.31M.
  • Rapport Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2169 holding.
  • Millennium Management first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.